Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Bio-Heart Biological Technology Co., Ltd. Class H ( (HK:2185) ) just unveiled an announcement.
Shanghai Bio-Heart Biological Technology Co., Ltd. reported its interim results for the first half of 2025, marking a significant milestone with the global launch of its first commercial product, the Iberis® 2nd RDN system. The company achieved a revenue of RMB20.9 million, a notable increase from the previous year. The Iberis® RDN system received approval from the NMPA and completed its first commercial procedure in Europe, enhancing the company’s market presence. Additionally, the SAKURA-SCB trial in Japan successfully enrolled its first patient, indicating progress in their research initiatives.
More about Shanghai Bio-Heart Biological Technology Co., Ltd. Class H
Shanghai Bio-Heart Biological Technology Co., Ltd. operates in the biotechnology industry, focusing on the development and commercialization of medical devices for cardiovascular diseases. The company’s primary product is the Iberis® RDN system, which is used for the treatment of resistant hypertension and patients with drug intolerance.
Average Trading Volume: 1,727,139
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.5B
See more insights into 2185 stock on TipRanks’ Stock Analysis page.